CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This program is intended for medical oncologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of bladder cancer.
  
  LEARNING OBJECTIVES

  • Review published clinical trial data leading to the FDA approval of erdafitinib for patients with advanced urothelial bladder cancer (UBC) and susceptible FGFR3 or FGFR2 genetic alterations whose disease has progressed during or after at least 1 line of platinum-containing chemotherapy, and determine how this agent may be appropriately integrated into clinical practice.
  • Recall pivotal clinical trial findings leading to the FDA approval of enfortumab vedotin for previously treated locally advanced or metastatic UBC, and identify patients for whom treatment with this novel compound would be appropriate.
  • Evaluate the recent FDA approval of the novel antibody-drug conjugate sacituzumab govitecan, and optimally integrate this agent into the care of patients with advanced UBC who have experienced disease relapse on chemotherapy and an immune checkpoint inhibitor.
  • Recognize how biologic and patient-specific factors influence the selection and sequencing of treatment for patients with advanced UBC.
  • Consider the available clinical trial evidence with immune checkpoint inhibitors in the treatment of UBC, and determine the current utility of these agents in clinical practice.
  • Appraise available research data and ongoing clinical trials evaluating anti-PD-1/PD-L1 antibodies alone or in combination with other systemic therapies for UBC, and counsel appropriately selected patients about participation in active protocols.
  • Develop an understanding of the biologic rationale for, available research findings with and ongoing studies evaluating promising investigational agents and strategies for UBC.

  ACCREDITATION STATEMENT
  Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
  
  CREDIT DESIGNATION STATEMENT
  CME credit is no longer available for this issue
  
  AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
  CME credit is no longer available for this issue
  
  HOW TO USE THIS CME ACTIVITY
  Audio Program: This CME activity consists of an audio component.
  CME credit is no longer available for this issue
  
  Video Program: This CME activity consists of a video component.
  CME credit is no longer available for this issue
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty reported relevant financial relationships with ineligible entities:
  
  Petros Grivas, MD, PhD
  Associate Professor, Department of Medicine
  Division of Oncology
  Clinical Director
  Genitourinary Cancers Program
  University of Washington
  Associate Member, Clinical Research Division
  Fred Hutchinson Cancer Research Center
  Seattle, Washington
  
  Advisory Committee and Consulting Agreements: 4D Pharma PLC, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Dyania Health, EMD Serono Inc, Exelixis Inc, Genentech, a member of the Roche Group, Genzyme Corporation, Gilead Sciences Inc, GlaxoSmithKline, Heron Therapeutics, Immunomedics Inc, Infinity Pharmaceuticals Inc, Janssen Biotech Inc, Merck, Mirati Therapeutics, Pfizer Inc, QED Therapeutics, Regeneron Pharmaceuticals Inc, Seagen Inc; Research Funding to Institution: Bavarian Nordic, Bristol-Myers Squibb Company, Clovis Oncology, Debiopharm Group, GlaxoSmithKline, Immunomedics Inc, Kure It Cancer Research, Merck, Mirati Therapeutics, Pfizer Inc, QED Therapeutics; Data and Safety Monitoring Board/Committee: Bristol-Myers Squibb Company.
  
  Daniel P Petrylak, MD
  Professor of Internal Medicine (Medical Oncology) and Urology
  Yale School of Medicine
  New Haven, Connecticut
  
  Consulting Agreements: Advanced Accelerator Applications, Amgen Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bicycle Therapeutics, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Clovis Oncology, Exelixis Inc, Incyte Corporation, Janssen Biotech Inc, Lilly, Mirati Therapeutics, Monopteros Therapeutics, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Regeneron Pharmaceuticals Inc, Roche Laboratories Inc, Seagen Inc, UroGen Pharma; Contracted Research: Advanced Accelerator Applications, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, BioXcel Therapeutics Inc, Bristol-Myers Squibb Company, Clovis Oncology, Eisai Inc, Endocyte Inc, Genentech, a member of the Roche Group, Innocrin Pharmaceuticals Inc, Lilly, Medivation Inc, a Pfizer Company, Merck, Mirati Therapeutics, Novartis, Pfizer Inc, Progenics Pharmaceuticals Inc, Replimune, Roche Laboratories Inc, Sanofi Genzyme, Seagen Inc; Ownership Interest: Bellicum Pharmaceuticals Inc, Tyme Inc.
  
  Arlene Siefker-Radtke, MD
  Professor
  Department of Genitourinary Medical Oncology
  Division of Cancer Medicine
  The University of Texas MD Anderson Cancer Center
  Houston, Texas
  
  Advisory Committee: AstraZeneca Pharmaceuticals LP, Basilea Pharmaceutica Ltd, Bristol-Myers Squibb Company, Genentech, a member of the Roche Group, IDEAYA Biosciences, Immunomedics Inc, Janssen Biotech Inc, Merck Sharp & Dohme Corp, Mirati Therapeutics, Nektar, Seagen Inc, Taiho Oncology Inc; Contracted Research: Basilea Pharmaceutica Ltd, Bristol-Myers Squibb Company, Janssen Biotech Inc, Merck Sharp & Dohme Corp, Nektar; Speakers Bureau (Nonpromotional): Janssen Biotech Inc.
  
  MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, Daiichi Sankyo Inc, Eisai Inc, Epizyme Inc, Exact Sciences Inc, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, Genentech, a member of the Roche Group, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc and Verastem Inc.
  
  RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
  
  This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  This activity is supported by educational grants from Astellas and Seagen Inc, AstraZeneca Pharmaceuticals LP, Gilead Sciences Inc, and Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC.
  
  Release date: August 2021
  Expiration date: August 2022